What is Zacks Research’s Forecast for Exelixis Q4 Earnings?

Exelixis, Inc. (NASDAQ:EXEL) – Investment analysts at Zacks Research cut their Q4 2026 earnings per share (EPS) estimates for Exelixis in a research note issued on Wednesday, August 26th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of $0.81 for the quarter, down from their prior forecast of $0.83. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $3.18 per share. Zacks Research also issued estimates for Exelixis’ Q2 2027 earnings at $0.84 EPS and Q3 2027 earnings at $0.93 EPS.

EXEL has been the subject of a number of other research reports. UBS Group set a $55.00 price objective on Exelixis in a report on Monday, August 3rd. Wall Street Zen lowered shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Wells Fargo & Company upped their price target on shares of Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a report on Monday, July 13th. Royal Bank Of Canada lifted their price objective on shares of Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings raised shares of Exelixis from a “buy (b)” rating to a “buy (a-)” rating in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Exelixis currently has an average rating of “Hold” and a consensus target price of $50.07.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $56.10 on Thursday. The firm has a market capitalization of $13.90 billion, a PE ratio of 17.64, a price-to-earnings-growth ratio of 1.69 and a beta of 0.44. The business has a 50 day simple moving average of $54.46 and a two-hundred day simple moving average of $48.88. Exelixis has a 1 year low of $33.76 and a 1 year high of $57.57.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The business had revenue of $628.69 million for the quarter, compared to analysts’ expectations of $636.40 million. During the same quarter in the previous year, the business posted $0.75 earnings per share. The business’s revenue was up 10.6% compared to the same quarter last year.

Institutional Trading of Exelixis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXEL. Sumitomo Mitsui Trust Group Inc. increased its position in Exelixis by 0.5% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock worth $2,549,000 after purchasing an additional 281 shares in the last quarter. Meeder Advisory Services Inc. lifted its position in Exelixis by 5.8% during the fourth quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock valued at $237,000 after buying an additional 298 shares in the last quarter. Cim LLC lifted its position in Exelixis by 0.9% during the third quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock valued at $1,462,000 after buying an additional 305 shares in the last quarter. J.W. Cole Advisors Inc. grew its stake in Exelixis by 6.5% during the fourth quarter. J.W. Cole Advisors Inc. now owns 5,354 shares of the biotechnology company’s stock worth $235,000 after buying an additional 329 shares during the period. Finally, Fifth Third Wealth Advisors LLC grew its stake in Exelixis by 3.8% during the first quarter. Fifth Third Wealth Advisors LLC now owns 9,077 shares of the biotechnology company’s stock worth $389,000 after buying an additional 333 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Activity at Exelixis

In other Exelixis news, Director Jack L. Wyszomierski sold 3,925 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $50.55, for a total value of $198,408.75. Following the completion of the sale, the director owned 284,384 shares of the company’s stock, valued at approximately $14,375,611.20. This trade represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mary C. Beckerle sold 9,812 shares of Exelixis stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the sale, the director owned 16,079 shares of the company’s stock, valued at $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 23,549 shares of company stock valued at $1,216,894 over the last 90 days. Insiders own 2.60% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.